Loading stock data…
BMEA
$1.37+0.01 (+0.74%)
Market ClosedLast close May 1
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biomea Fusion, Inc. in the Healthcare sector is trading at $1.37. The stock is currently 56% below its 52-week high of $3.08, remaining 10.5% below its 200-day moving average. Technical signals show neutral RSI of 31 and bearish MACD signal, explaining why BMEA maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 31) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.37
Potential Upside
5%
Whystock Fair Value$1.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$7.33+435.3%
Range$4.00 – $12.00
Fundamentals
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$133.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-379.30%
Volume
Today's trading volume
1.31M
Recent News
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company’s COVALENT-112 proof-of-concept study focused on safety, tolerability, and signals of beta cell function. Management said the results ma
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company’s lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator identified as Mike. The conversation centered on the scientific rationale for using menin inhibition i
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes. BMF-6
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
Biomea Fusion, Inc. (NASDAQ:BMEA) earns a place on our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock. With a consensus price target of $6.00, indicating a potential upside of 415.02%, analyst sentiment remains positive toward Biomea […]